Oral cyclosporin plus topical corticosteroid therapy diminishes bone mass in children with eczema

Pediatric Dermatology

Volumn 24, Issue 6, 2007, Pages 613-620

  Pedreira, Clarissa C ^a   King, Emma ^a   Jones, Graeme ^b   Moore, Elizabeth ^a   Zacharin, Margaret ^a   Varigos, George ^a   Cameron, Fergus J ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HYDROCORTISONE; MOMETASONE FUROATE;

ARTICLE; BONE DENSITY; BONE MASS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECZEMA; FEMALE; HUMAN; LUMBAR SPINE; MALE; PRIORITY JOURNAL; SIDE EFFECT;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, TOPICAL; BIOLOGICAL MARKERS; BONE DENSITY; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ECZEMA; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 36448949045     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2007.00549.x     Document Type: Article

References (58)

1. Leung D, Tharp M, Boguniewicz M. Atopic dermatitis (Atopic eczema). In : Freedberg IM, Eisen AZ, Wolff K et al., eds. Fitzpatrick's dermatology in general medicine 5th ed. New York : McGraw Hill Inc., 1999 : 1464 1480.
2. Feiwel M. Percutaneous absorption of topical steroids in children. Br J Dermatol 1969 81 (Suppl. 4 113 116.
3. Hosking GP, Elliston H. Benign intracranial hypertension in a child with eczema treated with topical steroids. Br Med J 1978 4 : 550.
4. Feinblatt BI, Aceto T, Beckhorn G et al. Percutaneous absorption of hydrocortisone in children. Am J Dis Child 1996 112 : 218 224.
5. Turpeinen M, Leisti S, Salo OP. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986 115 : 475 484.
6. Wolthers OD, Heuck C, Ternowitz T et al. Insulin-like growth factor axis, bone and collagen turnover in children with atopic dermatitis treated with topical glucocorticosteroids. Dermatology 1996 192 : 337 342.
7. Woo WK, McKenna KE. Iatrogenic adrenal gland suppression from use of a potent topical steroid. Clin Exp Dermatol 2003 28 : 672 673.
8. Cameron F. Down to skin and bone. Aust J Dermatol 2000 41 : 146 148.
9. Ma DQ, Jones G. Clinical risk factors but not bone density is associated with prevalent fractures in prepubertal children. J Paediatr Child Health 2002 38 : 497 500.
10. Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000 15 : 993 1000.
11. Russell RG, Graveley R, Skjodt H. The effects of cyclosporin A on bone and cartilage. Br J Rheumatol 1993 32 (Suppl. 1 42 46.
12. Goodman GR, Dissanayake IR, Sodam BR et al. Immunosuppressant use without bone loss - implications for bone loss after transplantation. J Bone Miner Res 2001 16 : 72 78.
13. Sakakura CE, Margonar R, Holzhausen M et al. Influence of cyclosporin A therapy on bone healing around titanium implants: a histometric and biomechanic study in rabbits. J Periodontol 2003 74 : 976 981.
14. Graziani G, Aroldi A, Castelnovo C et al. Ciclosporin and calcium metabolism in renal transplanted patients. Nephron 1991 57 : 479 480.
15. Rich GM, Mudge GH, Laffel GL et al. Cyclosporine A and prednisone-associated osteoporosis in heart transplant recipients. J Heart Lung Transplant 1992 11 : 950 958.
16. Shane E, Rivas MC, Silverberg SJ et al. Osteoporosis after cardiac transplantation. Am J Med 1993 94 : 257 264.
17. Sambrook PN, Kelly PJ, Keogh AM et al. Bone loss after heart transplantation: a prospective study. J Heart Lung Transplant 1994 13 : 116 120. Discussion 121.
18. Thiebaud D, Krieg MA, Gillard-Berguer D et al. Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 1996 26 : 549 555.
19. Sass DA, Bowman AR, Yuan Z et al. Alendronate prevents cyclosporin A-induced osteopenia in the rat. Bone 1997 21 : 65 70.
20. Cvetkovic M, Mann GN, Romero DF et al. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994 57 : 1231 1237.
21. Mann GN, Sass DA, Chen HK et al. Short-term systemic insulin-like growth factor-1 is unable to prevent cyclosporin A-induced osteopenia in the rat. Calcif Tissue Int 1996 59 : 38 44.
22. Movsowitz C, Epstein S, Fallon M et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988 123 : 2571 2577.
23. Kunz B, Ring J, Johannes R Clinical features and diagnostic criteria of atopic dermatitis. In : Harper J, Oranje A, Prose N eds. Textbook of paediatric dermatology, Vol. 1, Oxford : Blackwell Science, Inc., 2000 : 199 214.
24. Kunz B, Oranje A, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997 195 : 10 19.
25. Hardman JG, Limbird LE, Gillmas AG The pharmacological basis of therapeutics. 10th ed. New York : McGraw-Hill, Inc., 2001.
26. Ma D, Jones G. The association between bone mineral density, metacarpal morphometry and upper limb fractures in children: a population based case-control study. J Clin Endocrinol Metab 2003 88 : 1486 1491.
27. Barnes C, Wong P, Egan B et al. Reduced bone density in children with severe hemophilia. Pediatrics 2004 114 : e177 e181.
28. Barnes C, Newall F, Ignjatovic V et al. Reduced bone density in children on long-term warfarin. Pediatr Res 2005 57 : 578 581.
29. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992 7 : 137 145.
30. Tanner JM, Whitehouse RH, Cameron N et al. The assessment of skeletal maturity and the prediction of adult height (TW2 method). 2nd ed. London : Academic Press, Inc., 1983.
31. Jones G, Ma D. Skeletal age deviation assessed by the Tanner Whitehouse 2 method is associated with bone mass and fracture risk in children. Bone 2005 36 : 352 357.
32. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998 17 : 307 329.
33. Erben RG, Stangassinger M, Gartner R. Skeletal effects of low-dose cyclosporin A in aged male rats: lack of relationship to serum testosterone levels. J Bone Miner Res 1998 13 : 79 87.
34. Buchinsky FJ, Ma Y, Mann GN et al. T lymphocytes play a critical role in the development of cyclosporin A-induced osteopenia. Endocrinology 1996 137 : 2278 2285.
35. Epstein S, Dissanayake IR, Goodman GR et al. Effect of the interaction of parathyroid hormone and cyclosporine A on bone mineral metabolism in the rat. Calcif Tissue Int 2001 68 : 240 247.
36. Zeni SN, Gregorio S, Gomez AC et al. Olpadronate prevents the bone loss induced by cyclosporine in the rat. Calcif Tissue Int 2002 70 : 48 53.
37. Abdelhadi M, Ericzon BG, Hultenby K et al. Structural skeletal impairment induced by immunosuppressive therapy in rats: cyclosporine A vs tacrolimus. Transpl Int 2002 15 : 180 187.
38. Russell RG, Graveley R, Coxon F et al. Cyclosporin A. Mode of action and effects on bone and joint tissues. Scand J Rheumatol Suppl 1992 95 : 9 18.
39. Suzuki Y, Ichikawa Y, Saito E et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983 32 : 151 156.
40. Lukert BP, Stanbury SW, Mawer EB. Vitamin D and intestinal transport of calcium: effects of prednisolone. Endocrinology 1973 93 : 718 722.
41. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989 4 : 137 141.
42. Lukert BP. Glucocorticoid and drug-induced osteoporosis. In : Favus MJ ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 3rd ed. Philadelphia : Lippincott-Raven, 1996 : 278 282.
43. Lomenick JP, Backeljauw PF, Lucky AW. Growth, bone mineral accretion, and adrenal function in glucocorticoid-treated infants with hemangiomas - a retrospective study. Pediatr Dermatol 2006 23 : 169 174.
44. Leonard MB, Feldman HI, Shults J et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004 351 : 868 875.
45. Reid DM, Harvie J Secondary osteoporosis. In : Reid IR ed. Balliere's clinical endocrinology and metabolism. London : Bailliere Tindall, Inc., 1997 : 83 99.
46. McGoan R, Tucker P, Joseph D et al. Short-term growth and bone turnover in children undergoing occlusive steroid ('Wet-Wrap') dressings for treatment of atopic eczema. J Dermatolog Treat 2003 14 : 149 152.
47. Aalto-Korte K, Turpeinen M. Bone mineral density in patients with atopic dermatitis. Br J Dermatol 1997 136 : 172 175.
48. Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988 118 : 517 522.
49. Turpeinen M, Mashkilleyson N, Bjorksten F et al. Percutaneous absorption of hydrocortisone during exacerbation and remission of atopic dermatitis in adults. Acta Derm Venereol 1988 68 : 331 335.
50. Bronaugh RL, Weingarten DP, Lowe NJ. Differential rates of percutaneous absorption through the eczematous and normal skin of a monkey. J Invest Dermatol 1986 87 : 451 453.
51. Beamer WG, Donahue LR, Rosen CJ et al. Genetic variability in adult bone density among inbred strains of mice. Bone 1996 18 : 397 403.
52. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992 13 (Suppl. S7 S15.
53. Eisman JA, Kelly PJ, Morrison NA et al. Peak bone mass and osteoporosis prevention. Osteoporos Int 1993 3 (Suppl. 1 56 60.
54. Christiansen C. Osteoporosis: diagnosis and management today and tomorrow. Bone 1995 17 (5 Suppl. 513S 516S.
55. Melton LJ. Epidemiology of hip fractures; implications of the exponential increase with age. Bone 1996 18 (3 Suppl. 121S 125S.
56. Glastre C, Braillon P, David L et al. Measurement of bone mineral content of the lumbar spine by dual energy X-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab 1990 70 : 1330 1333.
57. De Schepper J, Derde MP, Van den Broeck M et al. Normative data for lumbar spine bone mineral content in children: influence of age, height, weight and pubertal stage. J Nucl Med 1991 32 : 216 220.
58. Cooley H, Jones G. A population based study of fracture incidence in southern tasmania: lifetime fracture risk and evidence for geographic variations within the same country. Osteoporos Int 2001 12 : 124 130.